The European Medicines Agency (EMA) has granted orphan drug status to AlphaCore Pharma's ACP-501 (rhLCAT) to treat familial LCAT deficiency (FLD). FLD causes lipid deposition in eyes, red blood cells and kidneys which can lead to corneal ...
Tags: EMA, orphan drug status, AlphaCore FLD